4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019)
4D Molecular Therapeutics (FDMT) reported Preferred Stock Liabilities of $103.0 million for Q4 2019.
4D Molecular Therapeutics (FDMT) Preferred Stock Liabilities (2019) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 1 years of Preferred Stock Liabilities data on file, last reported at $103.0 million in Q4 2019.
- Preferred Stock Liabilities for Q4 2019 came in at $103.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2019 was $103.0 million (changed N/A YoY), and the FY2019 annual result was $103.0 million, changed N/A from the prior year.
- Preferred Stock Liabilities steadied at $103.0 million in Q4 2019 per FDMT's latest filing.
- Over five years, Preferred Stock Liabilities peaked at $103.0 million in Q4 2019 and troughed at $103.0 million in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 102.98 Mn |